All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
#ASH24: Treatments for R/R AML, maintenance strategies, and mutation- and MRD-informed decisions
Bookmark this article
To update you on the exciting content presented at the 66th ASH Annual Meeting and Exposition, December 7–10, 2024, San Diego, US., we have collated our social media coverage. Catch up here with our live social media relating to management of relapsed/refractory (R/R) acute myeloid leukemia (AML), maintenance strategies, and mutation- and minimal residual disease (MRD)-informed treatment decisions.
CONGRESS | #ASH24 | EDUCATIONAL PRESENTATION
— AML Hub (@AML_Hub) December 8, 2024
Michael Heuser, @MHH_life, discusses the role of assessing a patient’s genotype to guide the selection of induction treatment in transplant-eligible patients with AML. He also emphasizes the importance of individualized MRD assessment… pic.twitter.com/0jZNfYUiu5
CONGRESS | #ASH24 | EDUCATIONAL PRESENTATION
— AML Hub (@AML_Hub) December 8, 2024
Courtney D. DiNardo, @MDAndersonNews, discusses mutation- and MRD-informed decisions and recent advancements in the treatment of older transplant-ineligible patients with AML. She highlights that while venetoclax has markedly improved… pic.twitter.com/2KgpkcEzYN
CONGRESS | #ASH24 | PRESENTATION
— AML Hub (@AML_Hub) December 7, 2024
Ibrahim Aldoss @cityofhope presents updated results from the phase II AUGMENT-101 trial.
With longer follow-up and a larger data set, revumenib continues to demonstrate clinically meaningful responses in patients with R/R KMT2Ar acute leukemias,… pic.twitter.com/9ICFXhqqCp
CONGRESS | #ASH24 | PRESENTATION@DrEmmaSearle @TheChristieNHS shares results from the phase I portion of the cAMeLot-1 trial of bleximenib monotherapy in patients with KMT2Ar or NPM1 mutated R/R acute leukemia.
— AML Hub (@AML_Hub) December 7, 2024
The RP2D was determined to be 100 mg BID, with a CR/CRh rate of 33%… pic.twitter.com/frHk4PxQVe
CONGRESS | #ASH24 | PRESENTATION
— AML Hub (@AML_Hub) December 7, 2024
Joshua Zeidner @LeukDocJZ @UNC_Lineberger highlights results from the phase I portion of the phase I/II DSP-5336-101 trial of enzomenib in patients with R/R acute leukemia.
Enzomenib was well-tolerated, with no DLTs, and showed promising activity… pic.twitter.com/yRfDEpgHfR
CONGRESS | #ASH24 | PRESENTATION@GhayasIssa @MDAndersonNews presents results from the phase I/II SAVE trial of revumenib plus ASTX727 and venetoclax in pediatric and adult patients with R/R AML.
— AML Hub (@AML_Hub) December 7, 2024
This all-oral regimen demonstrated high response rates, with an ORR of 82%, and an… pic.twitter.com/bU7QdSzYdF
CONGRESS | #ASH24 | PRESENTATION
— AML Hub (@AML_Hub) December 8, 2024
Jennifer Marvin-Peek @MDAndersonNews presents findings from an ongoing phase Ib/II trial of ivosidenib + Ven-Aza in IDH1m AML (N = 56 at cutoff date of March 2024).
▪️The triplet was efficacious, with ORR = 100% in patients with MDS/MPN, 97% in… pic.twitter.com/joOGcP18yv
CONGRESS | #ASH24 | PRESENTATION
— AML Hub (@AML_Hub) December 9, 2024
Loic Vasseur @VasseurLoic @HopSaintLouis discusses a study from the Acute Leukemia French Intergroup in patients with CBF-AML, using results from the CBF2006 and RetroCBF trials; CBF-specific centralized NGS was performed in 456 patients.
MRD in… pic.twitter.com/MOlj7NZLbI
CONGRESS | #ASH24 | POSTER
— AML Hub (@AML_Hub) December 11, 2024
Uma Borate @beatalleukemia @OSUCCC_James shares findings from the Beat AML Master trial (NCT03013998) regarding survival outcomes in older patients with ND AML harboring NPM1 mutations (n=207) or KMT2A rearrangements (n=39). The mOS was 18.4 months for… pic.twitter.com/PDZcQgot0F
CONGRESS | #ASH24 | PRESENTATION
— AML Hub (@AML_Hub) December 8, 2024
Carlos Jimenez-Vicente @cjimenezvicente @hospitalclinic @hematoclinicbcn presents results from a retrospective analysis that assessed the allo-HSCT refined ELN risk classification, with the new very poor risk group (adverse-plus), in patients with… pic.twitter.com/UZXi0s53yl
CONGRESS | #ASH24 | POSTER
— AML Hub (@AML_Hub) December 9, 2024
Arjan A. van de Loosdrecht, @amsterdamumc, presented results from the phase II ADVANCE-II trial (NCT03697707) evaluating vididencel monotherapy as a maintenance treatment in 20 patients with AML in first CR, who were MRD positive and ineligible for… pic.twitter.com/IGf45wXdpD
CONGRESS | #ASH24 | POSTER
— AML Hub (@AML_Hub) December 9, 2024
Joshua Zeidner @LeukDocJZ, @UNC_Lineberger, shared findings from a phase IIa trial evaluating SLS009 in combination with azacitidine and venetoclax in patients with R/R AML following prior venetoclax treatment (N=30). No dose-limiting toxicities,… pic.twitter.com/HW0qrF6qTG
CONGRESS | #ASH24 | POSTER
— AML Hub (@AML_Hub) December 9, 2024
Amir T Fathi, @harvardmed, presented interim findings from the phase Ia KOMET-007 trial (NCT05735184) evaluating ziftomenib combined with venetoclax/azacitidine in patients with R/R AML with NPM1 mutations or KMT2A rearrangements (N=54).
The combination… pic.twitter.com/ctpMPDvnwA
CONGRESS | #ASH24 | POSTER@EuniceWangMD, @RoswellPark, shared findings from a pooled analysis of patients with IDH1m R/R AML receiving olutasidenib + azacitidine in a phase I/II trial (NCT02719574; N=67). CR/CRh was achieved in 31% of patients, with a median duration of response… pic.twitter.com/lEKQDMySFX
— AML Hub (@AML_Hub) December 9, 2024
CONGRESS | #ASH24 | POSTER
— AML Hub (@AML_Hub) December 10, 2024
Chiara Sartor, @Unibo, presented results from the ongoing phase II Gimema AML2521 trial (NCT04867928), investigating venetoclax + azacitidine for preventing morphological relapse in adult patients (N=20) with NPM1m AML experiencing molecular failure. At… pic.twitter.com/di6xILPAI7
CONGRESS | #ASH24 | PRESENTATION
— AML Hub (@AML_Hub) December 9, 2024
Eric S. Winer @DanaFarber discusses preliminary safety, efficacy, and potential biomarkers of emavusertib in patients with R/R AML in the phase I/II TakeAim Leukemia trial.
Emavusertib demonstrated promising activity, with results indicating that… pic.twitter.com/o0DcNK81OJ
CONGRESS | #ASH24 | POSTER@prateekpophali @BIDMChealth @harvardmed shares findings from a phase II trial of dendritic cell/AML fusion cell vaccination (n=27) vs SoC (n=14) in AML patients in CR1 who were not proceeding to HSCT.
— AML Hub (@AML_Hub) December 10, 2024
In vaccinated patients, 2-year PFS was 36% and… pic.twitter.com/rkYp4HcG4o
CONGRESS | #ASH24 | POSTER
— AML Hub (@AML_Hub) December 10, 2024
Alexandre Bazinet @MDAndersonNews presents findings from a phase I study of oral maintenance with decitabine/cedazuridine plus physician’s choice of targeted therapy (venetoclax, gilteritinib, enasidenib or ivosidenib) in patients with AML in CR1 (N =… pic.twitter.com/eShoWWIvZn
Your opinion matters
33 votes - 31 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox